Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field
Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing dissemin...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2019
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/24049
- Acceso en línea:
- https://doi.org/10.1080/14760584.2019.1583558
https://repository.urosario.edu.co/handle/10336/24049
- Palabra clave:
- BCG vaccine
Cytokine
Animal model
Bacterial load
Drug efficacy
Experimental model
Guinea pig model
Human
In vitro study
Nonhuman
Primate model
Priority journal
Review
Survival
Tuberculosis
Zebra fish
Animal model
Mycobacterium spp
Tuberculosis
Vaccine
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_54c6d521efd7a47286287e8ef50d3884 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/24049 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
a2ce4e55-0be6-4e55-9c67-92ab62617474-129ed545e-1ec1-4586-800c-4a2758cab090-19fc64f6d-a903-48f1-ac2e-4e55fd2ed9af-12020-05-26T00:08:02Z2020-05-26T00:08:02Z2019Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages; however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria, and its efficacy decreases with a host’s age. Areas covered: Following a comprehensive search of the available literature, this review describes some of the most frequently used animal models, the most frequently used methods for evaluating efficacy in animal models and some in vitro strategies as alternatives for evaluating vaccines. Expert opinion: Identifying the animal models used up to now for evaluating vaccines during their development stages, their characteristics and limitations, as well as knowledge regarding strategies for evaluating promising vaccine candidate efficacy, will ensure more efficient, reliable and reproducible pre-clinical trials. Although much of the knowledge accrued to date concerning vaccine effectiveness against tuberculosis has been based on animal models, it is clear that large questions still need to be resolved and that extrapolation of such efficacy to humans has yet to be achieved. © 2019, © 2019 Informa UK Limited, trading as Taylor and Francis Group.application/pdfhttps://doi.org/10.1080/14760584.2019.158355814760584https://repository.urosario.edu.co/handle/10336/24049engTaylor and Francis Ltd377No. 4365Expert Review of VaccinesVol. 18Expert Review of Vaccines, ISSN:14760584, Vol.18, No.4 (2019); pp. 365-377https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063743028&doi=10.1080%2f14760584.2019.1583558&partnerID=40&md5=14410216e9e2b4040a334f2b06766fdbAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURBCG vaccineCytokineAnimal modelBacterial loadDrug efficacyExperimental modelGuinea pig modelHumanIn vitro studyNonhumanPrimate modelPriority journalReviewSurvivalTuberculosisZebra fishAnimal modelMycobacterium sppTuberculosisVaccineExperimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the fieldarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Mantilla Galindo A.Ocampo M.Patarroyo M.A.10336/24049oai:repository.urosario.edu.co:10336/240492022-05-02 07:37:14.892954https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
title |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
spellingShingle |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field BCG vaccine Cytokine Animal model Bacterial load Drug efficacy Experimental model Guinea pig model Human In vitro study Nonhuman Primate model Priority journal Review Survival Tuberculosis Zebra fish Animal model Mycobacterium spp Tuberculosis Vaccine |
title_short |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
title_full |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
title_fullStr |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
title_full_unstemmed |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
title_sort |
Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field |
dc.subject.keyword.spa.fl_str_mv |
BCG vaccine Cytokine Animal model Bacterial load Drug efficacy Experimental model Guinea pig model Human In vitro study Nonhuman Primate model Priority journal Review Survival Tuberculosis Zebra fish Animal model Mycobacterium spp Tuberculosis Vaccine |
topic |
BCG vaccine Cytokine Animal model Bacterial load Drug efficacy Experimental model Guinea pig model Human In vitro study Nonhuman Primate model Priority journal Review Survival Tuberculosis Zebra fish Animal model Mycobacterium spp Tuberculosis Vaccine |
description |
Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages; however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria, and its efficacy decreases with a host’s age. Areas covered: Following a comprehensive search of the available literature, this review describes some of the most frequently used animal models, the most frequently used methods for evaluating efficacy in animal models and some in vitro strategies as alternatives for evaluating vaccines. Expert opinion: Identifying the animal models used up to now for evaluating vaccines during their development stages, their characteristics and limitations, as well as knowledge regarding strategies for evaluating promising vaccine candidate efficacy, will ensure more efficient, reliable and reproducible pre-clinical trials. Although much of the knowledge accrued to date concerning vaccine effectiveness against tuberculosis has been based on animal models, it is clear that large questions still need to be resolved and that extrapolation of such efficacy to humans has yet to be achieved. © 2019, © 2019 Informa UK Limited, trading as Taylor and Francis Group. |
publishDate |
2019 |
dc.date.created.spa.fl_str_mv |
2019 |
dc.date.accessioned.none.fl_str_mv |
2020-05-26T00:08:02Z |
dc.date.available.none.fl_str_mv |
2020-05-26T00:08:02Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1080/14760584.2019.1583558 |
dc.identifier.issn.none.fl_str_mv |
14760584 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/24049 |
url |
https://doi.org/10.1080/14760584.2019.1583558 https://repository.urosario.edu.co/handle/10336/24049 |
identifier_str_mv |
14760584 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
377 |
dc.relation.citationIssue.none.fl_str_mv |
No. 4 |
dc.relation.citationStartPage.none.fl_str_mv |
365 |
dc.relation.citationTitle.none.fl_str_mv |
Expert Review of Vaccines |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 18 |
dc.relation.ispartof.spa.fl_str_mv |
Expert Review of Vaccines, ISSN:14760584, Vol.18, No.4 (2019); pp. 365-377 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063743028&doi=10.1080%2f14760584.2019.1583558&partnerID=40&md5=14410216e9e2b4040a334f2b06766fdb |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Taylor and Francis Ltd |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167633805705216 |